Impact of Tocilizumab on the Mortality of Patients With Coronavirus Disease 2019
Clin Infect Dis
.
2021 Jun 15;72(12):e1156-e1157.
doi: 10.1093/cid/ciaa1738.
Authors
Yu-Tien Huang
1
,
Chien-Ming Chao
2
,
Chih-Cheng Lai
3
Affiliations
1
Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
2
Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
3
Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan.
PMID:
33201178
PMCID:
PMC7717218
DOI:
10.1093/cid/ciaa1738
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Substances
Antibodies, Monoclonal, Humanized
tocilizumab